Primary endpoint analysis at 1 year showed better maintenance of erectile function and pad-free continence with TULSA than with robotic radical prostatectomy. Peri-procedural metrics favored TULSA, ...

TORONTO, March 27, 2026 (GLOBE NEWSWIRE)-- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets AI-powered, ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

In a randomized trial, half of patients who received TULSA maintained both pad-free continence and erections at 6 months compared with one-quarter who had RP. Magnetic resonance imaging (MRI)-guided ...

A new randomized clinical trial found that men with localized, intermediate‑risk prostate cancer recovered faster and experienced less short‑term impact on their daily lives when treated with ...

Detailed price information for Profound Medical Corp (PROF-Q) from The Globe and Mail including charting and trades.

Newswise — UC San Diego Health is leading the region in offering a novel treatment for prostate cancer called transurethral ultrasound ablation or TULSA. The MRI-guided procedure uses a urethral probe ...

TORONTO, May 14, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative ...

KIMS Hospitals in Hyderabad has introduced Tulsa-Pro, an advanced prostate cancer treatment system developed by Canada's Profound Medical Corp.

TORONTO, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, ...